Following up on last month’s meeting with President Obama, the American Medical Association, the American Hospital Association, America’s Health Insurance Plans, Phrma, and more sent the President a letter with more detailed suggestions on bending the health care cost curve. Also today, the GAO released a report on FEHB plan member cost sharing for specialty or biologic drugs. The PBM trade association, PCMA, points out that Congress could start bending the curve by passing a law that creates a regulatory pathway for lower priced “bio-similar” drugs. Good point.